Boundless Bio (BOLD) vs Clene (CLNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Boundless Bio (BOLD) has outperformed Clene (CLNN) over the past year, gaining 98.5% versus a loss of 58.8%. Boundless Bio is the larger company by market cap ($58.7 million vs $55.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | CLNN |
|---|---|---|
| Share price | $2.58 | $3.88 |
| Market cap | $58.69M | $55.15M |
| 1-day change | -2.27% | -1.02% |
| YTD return | +115.00% | -33.90% |
| 1-year return | +98.46% | -58.81% |
| 5-year return | — | -96.86% |
| EPS (TTM) | $-2.80 | $-3.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $13.50 |
| 52-week low | $0.961 | $3.25 |
| Distance from 52-week high | -18.46% | -71.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +55.04% | +729.90% |
| Average volume | 182.04K | 100.21K |
| Shares outstanding | 22.75M | 14.21M |
| Employees | 28 | 76 |
| Sector | Healthcare | Consumer Defensive |
| Industry | Biotechnology | Packaged Foods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed CLNN by 157.3 percentage points over the past year.
- The two companies sit in different sectors: Boundless Bio in Healthcare and Clene in Consumer Defensive.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Healthcare · Biotechnology · 28 employees
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Consumer Defensive · Packaged Foods · 76 employees
BOLD vs CLNN FAQ
Which is bigger, Boundless Bio or Clene?
Boundless Bio (BOLD) is larger, with a market capitalization of $58.69M compared with $55.15M for Clene (CLNN).
Which stock has performed better over the past year, BOLD or CLNN?
BOLD returned +98.46% over the past 12 months, compared with -58.81% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Clene in the same industry?
No. Boundless Bio is in the Healthcare sector, while Clene is in Consumer Defensive.